Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | PTGFR | P43088 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31366256 | 1.00 | KMT2A (0.38) | KMT2ANPC1RAB9AHPGDKMO | |
| SCHEMBL30326005 | 0.84 | RAB9A (0.38) | KMT2ANPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL22256745 | 0.82 | NPC1 (0.40) | KMT2ANPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL30326198 | 0.79 | CYP4F2 (0.39) | KMT2ANPC1RAB9AHPGDKDM4E | |
| SCHEMBL20517447 | 0.79 | NPC1 (0.41) | KMT2ANPC1RAB9AHPGDKDM4E | |
| SCHEMBL30600870 | 0.79 | NPC1 (0.41) | KMT2ANPC1RAB9AHPGDKDM4E | |
| SCHEMBL20517639 | 0.79 | ALDH1A1 (0.36) | KMT2ANPC1RAB9AHPGDKDM4E | |
| SCHEMBL18420384 | 0.79 | CYP4F2 (0.39) | KMT2ANPC1RAB9AHPGDKDM4E | |
| SCHEMBL30600776 | 0.79 | ALDH1A1 (0.36) | KMT2ANPC1RAB9AHPGDKDM4E | |
| SCHEMBL2790057 | 0.79 | HPGD (0.39) | KMT2AHPGDKMOKDM4EHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-112771027-B | Lysophosphatidic acid receptor antagonists and process for preparing the same | 武汉朗来科技发展有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | UCB Biopharma SRL (BE) | 2024-02-27 | — | — | US | disclosed |
| CN-117024411-A | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-110709392-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2022-03-17 | — | — | US | disclosed |
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2022-03-17 | — | — | US | disclosed |
| EP-3601259-B1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HOFFMANN LA ROCHE (CH) | 2022-02-23 | — | — | EP | disclosed |
| US-20170305932-A1 | Fused Pentacyclic Imidazole Derivatives | SANOFI (FR) | 2017-10-26 | — | — | US | disclosed |
| CN-107108672-A | The five rings imdazole derivatives of fusion | UCB生物制药私人有限公司 | 2017-08-29 | — | — | CN | disclosed |
| EP-3201196-A1 | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES | UCB Biopharma SPRL (BE) | 2017-08-09 | — | — | EP | disclosed |
| EP-3080115-A1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| US-20160297837-A1 | Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity | EVOTEC (UK) LTD. (GB) | 2016-10-13 | — | — | US | disclosed |
| CN-105814054-A | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| WO-2016050975-A1 | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-07 | — | — | WO | disclosed |
| WO-2015086506-A1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| EP-2513128-A2 | MANNOSE DERIVATIVES AS ANTAGONISTS OF BACTERIAL ADHESION | University of Basel (CH) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011073112-A2 | MANNOSE DERIVATIVES AS ANTAGONISTS OF BACTERIAL ADHESION | UNIVERSITY OF BASEL (CH) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | LPAR1, LPAR2, LPAR4 | KMT2A 1702/4885NPC1 520/4885RAB9A 1177/4885 |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | TNF, NFKBIA, TNFRSF1A | KMT2A 2464/4885NPC1 2668/4885RAB9A 1534/4885 |
| US-20160297837-A1 | Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | KMT2A 4312/4885NPC1 3608/4885RAB9A 1151/4885 |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | HIPK1, HIPK2, IP6K1 | KMT2A 1099/4885NPC1 1022/4885RAB9A 2736/4885 |
| US-20170305932-A1 | Fused Pentacyclic Imidazole Derivatives | TNF, NFKBIA, TNFRSF1A | KMT2A 2464/4885NPC1 2668/4885RAB9A 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.